MedComm 潤色咨詢

MedComm

出版年份:暫無數(shù)據(jù) 年文章數(shù):94 投稿命中率: 開通期刊會員,數(shù)據(jù)隨心看

出版周期:暫無數(shù)據(jù) 自引率:暫無數(shù)據(jù) 審稿周期: 開通期刊會員,數(shù)據(jù)隨心看

前往期刊查詢

投稿信息

投稿信息
審稿費用
暫無數(shù)據(jù)
版面費用
暫無數(shù)據(jù)
中國人發(fā)表比例
2023年中國人文章占該期刊總數(shù)量暫無數(shù)據(jù) (2022年為84.71%)
自引率
暫無數(shù)據(jù)
年文章數(shù)
94
期刊官網(wǎng)
點擊查看 (點擊次數(shù):5208)
投稿鏈接
點擊查看 (點擊次數(shù):1804次)
作者需知
點擊查看 (點擊次數(shù):1109次)
期刊簡介
稿件收錄要求

Aim of the journal

MedComm?is a peer-reviewed, online open access journal that publishes the pioneer works providing novel insights into all aspects of medicine on the basis of novelty, timeliness and significance to human health. The journal emphasizes original findings that advance the understanding of pathogenesis or improve the diagnosis and treatment of human disease. Interdisciplinary studies utilizing approaches of molecular biology, cell biology, chemistry, pharmacology or material science to address the issues of clinical, basic and translational medicines are particularly encouraged.

Scope and topics (including keywords)

MedComm?is interested in topics including but not limited to clinical medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug discovery, nanotechnology and artificial intelligence. The journal focuses on clinical and experimental advances on disease characteristics, pathogenic mechanism and medical techniques.

Topics of interest include, but are not limited to:

  • Epigenetics, genomics, proteomics and metabonomics
  • Non-coding RNA in disease
  • Cell senescence and cell death
  • Cellular signal transduction
  • Gene therapy and gene editing
  • Cancer immunology and immunotherapy
  • Structural biology, chemical genomics and drug discovery
  • High-definition imaging
  • Artificial intelligence in medicine
  • Stem cells and regenerative medicine
  • Nanomedicine and drug delivery system
  • Early disease diagnosis and biomarkers
  • Clinical trials evaluating new treatments for cancer or other diseases